The Annual Report for the Financial Year 2025-26 and Notice of the 23rd (Twenty-Third) Annual General Meeting (''AGM'') of the Company.

Ref. No.: CIAN/BSE/2026-27/21 Friday, September 04, 2026 The Manager-Listing BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 542678 Trading Symbol: CHCL Subject: Annual Report for the financial year ended March 31, 2026, including the Notice of 23rd (Twenty-Third) Annual General Meeting of Cian Healthcare Limited in accordance with the provisions of Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Reference: Outcome of the Board meeting dated September 02, 2026, bearing reference no. CIAN/BSE/2026-27/19 made pursuant to Regulation 30 read with Schedule III to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, ln compliance with the Regulation 34 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and other applicable master circulars, circulars, guidelines, regulations and notifications, as issued by the Securities and Exchange Board of India (“SEBI”), we, Cian Healthcare Limited (“Company”), would like to present the Annual Report for the financial year ended March 31, 2026 and notice of 23rd (Twenty-Third) Annual General Meeting (“AGM”) of the Company, which is scheduled to be held on Tuesday, September 29, 2026, at 11:00 a.m. (IST) through Video Conferencing/ Other Audio Visual Means (VC/ OAVM) facility. The aforesaid documents are being sent electronically to those Members whose e-mail ids are registered with the Company/Bigshare Services Private Limited (Registrar and Share Transfer Agent of the Company) or the Depositories and the physical copies of the same will be provided to the Members on request. Further, in compliance with Regulation 36(1)(b) of the Listing Regulations, the Company is the process of dispatching letter(s) to those Members whose e-mail addresses are not registered with the Company, the Registrar and Share Transfer Agent, or the Depository Participant(s), providing the weblink, along with the exact path to access the complete details of the Annual Report of the Company for the Financial Year 2025-26 and the Notice of the 23rd AGM, as hosted on the Company’s website. The PDF version of the Annual Report for the financial year 2025-26 and the Notice of AGM are hosted on the website of the Company and Bigshare Services Private Limited, which can be accessed/downloaded from the web links https://cian.co/ and https://ivote.bigshareonline.com, respectively. Kindly take the above information on record and oblige. Thanking You For Cian Healthcare Limited Rachit Malhotra Company Secretary and Chief Compliance Officer Membership No.: A39894 Place: New Delhi Enclosed: As above ANNUAL REPORT 2025-26 Science-led care. Everyday wellbeing. Contents Statutory Reports Standalone Financial Statements 03 Consolidated Financial Statements 04 Notice Four clear gateways into the report STATUTORY REPORTS Governance, accountability and responsible stewardship MANUFACTURING • QUALITY Board’s Report CIAN HEALTHCARE LIMITED Corporate Identity Number (CIN): L24233PN2003PLC017563 Regd. Office: 301, 3 Floor, Konark Icon, Mundhwa-Kharadi Road, Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra-411028, Phone No.: +91 9049000648, Corporate Office: 606, Ring Road Mall, Sector-3, Rohini, New Delhi-110085, Phone No.: 011-49120841 Website: https://cian.co/, Email: cs@cian.co BOARD’S REPORT The Members of Cian Healthcare Limited, Your directors are pleased to present the Board's Report (“Report”) of Cian Healthcare Limited (“Company”) in accordance with the Companies Act, 2013 (“Act”) read with rules made thereunder. This Report covers the financial highlights of the Audited (Standalone and Consolidated) Financial Statements (“Financial Statements”) and other developments in respect of the Company during the Financial Year ended on March 31, 2026 (“Financial Year”) and any other material development up to the date of this Report. 1. STATUS OF PROCEEDINGS UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 IN RELATION TO CORPORATE INSOLVENCY RESOLUTION PROCESS DURING THE FINANCIAL YEAR 2025-26: Members are informed that the Company underwent Corporate Insolvency Resolution Process ("CIRP") under the Insolvency and Bankruptcy Code, 2016 ("Code"). The CIRP was triggered pursuant to a petition filed by Shreeji Pharmachem, an Operational Creditor, under Section 9 of the Code, which was admitted by the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") vide its order dated June 11, 2024. Pursuant thereto, Mr. Roshen Chordiya (IBBI Registration No.: IBBI/IPA-001/IP-P02840/2023-2024/14347) was appointed as the Interim Resolution Professional ("IRP") of the Company. Subsequently, the Company arrived at a settlement with the Operational Creditor, pursuant to which the IRP filed an application for withdrawal of the CIRP. The Hon'ble NCLT, being satisfied that the settlement had been reached prior to constitution of the Committee of Creditors ("COC"), allowed the withdrawal vide its order dated June 20, 2024. On account of subsequent default in the settlement terms, the Operational Creditor filed a Restoration Application, which was admitted by the Hon'ble NCLT vide its order dated August 14, 2024, thereby restoring the CIRP with effect from June 11, 2024, with commencement timelines reckoned from August 14, 2024, pursuant to the deferment sought by the IRP. The COC, at its meeting held on February 12, 2025, confirmed the appointment of Mr. Roshen Chordiya as the Resolution Professional ("RP"), who thereupon assumed control and custody of the management and operations of the Company. Of the resolution plans placed before the COC, the plan submitted by Mr. Pradeep Kumar Jain, the Successful Resolution Applicant ("SRA"), was unanimously approved by the COC at its meeting held on March 28, 2025, and was thereafter filed before the Hon'ble NCLT under Sections 30(6) and 31(1) of the Code read with Regulation 39 of the IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016. The Hon'ble NCLT approved the resolution plan vide its order dated December 18, 2025 ("NCLT Order" / "NCLT Approval Date"), which was duly intimated to the relevant statutory and regulatory authorities. Board’s Report Constitution of the Resolution Plan Implementation Committee Pursuant to the NCLT Order, the Company constituted a Resolution Plan Implementation Committee ("Implementation Committee") with effect from the NCLT Approval Date, to remain in existence until the Resolution Plan Closure Date (as defined under the approved resolution plan), such intervening period being referred to as the "Resolution Plan Implementation Period". The Implementation Committee comprised the following: S.No. Composition Designation 1. Mr. Roshen Chordiya, Resolution Professional Chairperson Mr. Sumit N. Kurup, Nominee of IDBI Bank 2. Member (on behalf of the Committee of Creditors) 3. Mr. Rachit Malhotra, Nominee of the Successful Resolution Applicant Member The Implementation Committee was vested with powers coextensive with those of the Board of Directors under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, exercisable strictly during the Resolution Plan Implementation Period and solely for implementation-related purposes including oversight of stakeholder payments as contemplated under the approved resolution plan, statutory and ancillary filings, and compliance with applicable law and directions of the Hon'ble NCLT, so as to ensure operational continuity of the Company. Dissolution of the Implementation Committee: Upon successful implementation of the resolution plan, the mandate of the Implementation Committee stood concluded, and it was accordingly dissolved with effect from February 1, 2026, consequent to completi [Showing first 8,000 characters — download PDF for full document]